🔬 What is the Test?
The Acute Leukemia MRD (Minimal Residual Disease) Panel & Relapse Test detects very low levels of leukemia cells remaining after treatment. It helps evaluate the effectiveness of therapy, assess relapse risk, and guide further treatment decisions.
📊 Normal Ranges:
MRD Negative (No detectable leukemia cells): Favorable prognosis
MRD Positive (Detectable residual leukemia cells): Increased relapse risk, requiring further treatment
(Results should be interpreted alongside clinical evaluation and other lab findings.)
🎯 Purpose of the Test:
✅ Determines if leukemia treatment was successful
✅ Detects remaining leukemia cells at extremely low levels (as low as 1 in 10,000 cells)
✅ Assesses relapse risk and need for additional treatment
✅ Guides personalized treatment adjustments (e.g., chemotherapy, stem cell transplant, targeted therapy)
🩺 When is it Recommended?
🔹 After leukemia treatment (chemotherapy, radiation, or transplant) to assess residual disease
🔹 For monitoring treatment response and identifying potential relapse early
🔹 For adjusting treatment plans based on MRD status
📝 How is the Test Done?
1️⃣ Sample Collection – Blood or bone marrow sample is taken.
2️⃣ Laboratory Analysis – Flow cytometry, PCR, and Next-Generation Sequencing (NGS) detect minimal leukemia cells.
3️⃣ Result Interpretation – Helps determine if additional treatment is necessary.
⚠️ What Do Abnormal Results Mean?
📉 MRD Negative:
No detectable leukemia cells, indicating a lower risk of relapse
📈 MRD Positive:
Residual leukemia cells detected, suggesting possible relapse risk
May require further treatment like intensified chemotherapy or a stem cell transplant
📌 Infographic Design Idea:
✔ Medical color scheme (blue, white, and red)
✔ Illustration of leukemia cells and MRD detection process
✔ Flowchart explaining MRD testing and treatment decisions
✔ Table summarizing MRD negative vs. MRD positive results and their significance